Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET

Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET

Detecting tumor lesions <1 cm in size using current imaging methods remains a clinical challenge, especially in pancreatic cancer. Previously, we developed a method to identify pancreatic tumor lesions ≥3 mm using positron emission tomography (PET) with an intraperitoneally administered <sup&g...

Full description

Bibliographic Details
Main Authors: Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, Kimiteru Ito, Tatsuya Higashi, Yukie Yoshii
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Pharmaceutics
Subjects:
<sup>64</sup>Cu-NCAB001
ipPET
preclinical safety
extended single dose toxicity study
Online Access:https://www.mdpi.com/1999-4923/14/9/1928

Internet

https://www.mdpi.com/1999-4923/14/9/1928

Similar Items